Comparative Pharmacology
Head-to-head clinical analysis: METRETON versus METROCREAM.
Peer-Reviewed Evidence
Head-to-head clinical analysis: METRETON versus METROCREAM.
METRETON vs METROCREAM
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Antihistamine and mast cell stabilizer. Competitively inhibits histamine at H1 receptors and prevents release of histamine and other mediators from mast cells.
Metrocream contains metronidazole, a nitroimidazole antibiotic. Its mechanism involves reduction of the nitro group by bacterial nitroreductases, forming toxic intermediates that damage DNA and inhibit nucleic acid synthesis. It also exhibits anti-inflammatory effects by reducing reactive oxygen species and modulating neutrophil chemotaxis.
1-2 mg/kg intramuscularly or intravenously every 6-8 hours as needed; maximum 100 mg per dose.
Topical, apply a thin film to affected area once or twice daily.
None Documented
None Documented
Terminal elimination half-life is 24-36 hours; increased in renal impairment (up to 60 hours in anuria)
Terminal elimination half-life: 6-8 hours. Not extended in renal impairment.
Renal (80-90% as unchanged drug and metabolites), biliary/fecal (10-20%)
Renal: 70-80% as unchanged drug and metabolites. Fecal/biliary: ~20%.
Category C
Category C
Antibiotic (Nitroimidazole)
Antibiotic (Nitroimidazole)